Perfect Clean: Clean Matters

From the first in-person APIC Annual Conference in three years, Karl Baker, Senior VP of Sales and Marketing at Perfect Clean, recognized how vital in-person interactions are to collaboration and networking. “Networking in person, which hasn’t been possible in the virtual forums,” explained Baker.

In the event’s 50th year, Lurlie Moro, SE Regional Manager of Perfect Clean, said, “it’s a critical meeting to gather all infection preventionists to gather their knowledge.” Perfect Clean joined the event as a strategic partner this year. APIC does a great job of bringing people together. Baker said that “commitment to excellence and their recognition of excellence” is fundamental to making the conference what it is.

Baker and Moro witnessed trends in the work of infection prevention, the crossover of departments for collaboration, and support for their teams in the wake of the pandemic. Baker said, “there’s a lot more focus on recognizing the work behind the scenes they have put in place.”

Perfect Clean focused on connecting with clients, collaborating with partners, and showcasing products. UMF Corporation’s products include PerfectCLEAN, Micrillon, PCIPAD, LENStronic, and the C-PULL. These products are designed to reduce preventative HAI’s (healthcare-acquired infections) and are deployed using an ONEperROOM methodology which is designed to prevent patient room-to-room cross-contamination.

Moro wanted clients to take away that the Perfect Clean product line has been tried and tested. “[This year] we’re focusing on what we offer is rooted in science,” said Moro. It’s evidence-based and backed by third-party testing to prove effectiveness. This was critical, in addition to showing potential clients that their products are practical and easy to use and implement.

Listen to the episode now for more insights from the APIC 2022 Conference. For more information on the Perfect Clean line of products, visit www.perfectclean.com.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More